share_log

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A：證券上市註冊聲明(修正)
美股SEC公告 ·  09/12 17:14

Moomoo AI 已提取核心訊息

180 Life Sciences Corp. has announced an offering of up to 3,296,703 shares of common stock, pre-funded warrants to purchase an equivalent number of shares, and common warrants to purchase up to the same number of shares. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants have an assumed initial exercise price of $1.82 per share, equal to the last reported sales price of the company's common stock on Nasdaq as of September 10, 2024. These common warrants will be exercisable upon obtaining stockholder approval or immediately if certain pricing conditions are met. The offering is being conducted on a 'reasonable best efforts' basis by A.G.P./Alliance Global Partners as the sole placement agent. The company intends to use the net proceeds for research and development expenses, transaction costs to complete a strategic transaction, legal expenses, and working capital. The offering is expected to close on or about the date of the prospectus, subject to customary closing conditions.
180 Life Sciences Corp. has announced an offering of up to 3,296,703 shares of common stock, pre-funded warrants to purchase an equivalent number of shares, and common warrants to purchase up to the same number of shares. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants have an assumed initial exercise price of $1.82 per share, equal to the last reported sales price of the company's common stock on Nasdaq as of September 10, 2024. These common warrants will be exercisable upon obtaining stockholder approval or immediately if certain pricing conditions are met. The offering is being conducted on a 'reasonable best efforts' basis by A.G.P./Alliance Global Partners as the sole placement agent. The company intends to use the net proceeds for research and development expenses, transaction costs to complete a strategic transaction, legal expenses, and working capital. The offering is expected to close on or about the date of the prospectus, subject to customary closing conditions.
180 Life Sciences Corp. 宣佈發行多達 3,296,703 股普通股、預資金化認購權證以購買等量股份和普通認購權證以購買相同數量的股份。預資金化認購權證每股行使價格爲 $0.0001，可立即行使。普通認購權證的假定初始行使價格爲每股 $1.82，等於2024年9月10日納斯達克公司普通股的最後報價。這些普通認購權證將在獲得股東批准後或在滿足某些定價條件的情況下立即行使。該發行是由唯一的配售代理商A.G.P./Alliance Global Partners以"合理盡力"的方式進行。公司打算將募集資金用於研發費用、完成戰略交易的交易費用、法律費用和營運資本。該發行預計將在招股說明書的約定日期前後關閉，須符合一般約定的關閉條件。
180 Life Sciences Corp. 宣佈發行多達 3,296,703 股普通股、預資金化認購權證以購買等量股份和普通認購權證以購買相同數量的股份。預資金化認購權證每股行使價格爲 $0.0001，可立即行使。普通認購權證的假定初始行使價格爲每股 $1.82，等於2024年9月10日納斯達克公司普通股的最後報價。這些普通認購權證將在獲得股東批准後或在滿足某些定價條件的情況下立即行使。該發行是由唯一的配售代理商A.G.P./Alliance Global Partners以"合理盡力"的方式進行。公司打算將募集資金用於研發費用、完成戰略交易的交易費用、法律費用和營運資本。該發行預計將在招股說明書的約定日期前後關閉，須符合一般約定的關閉條件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間